What is InspireMD?
InspireMD, Inc. operates as a medical device company dedicated to the development and commercialization of its unique MicroNet stent platform technology. This innovative technology is designed for the treatment of vascular and coronary diseases, with a strategic focus on making its products the benchmark for carotid stenting. The company's objective is to achieve superior acute results and durable, stroke-free long-term outcomes for patients. InspireMD's common stock is publicly traded on the NYSE American under the ticker symbol NSPR, with certain warrants also available on the NYSE American under symbols NSPR.WS and NSPR.WSB. The company is headquartered in Tel Aviv, Israel.
How much funding has InspireMD raised?
InspireMD has raised a total of $109.1M across 3 funding rounds:
Debt
$11M
Private Equity
$40.1M
Stock/Share Issuance
$58M
Debt (2012): $11M, investors not publicly disclosed
Private Equity (2025): $40.1M, investors not publicly disclosed
Stock/Share Issuance (2025): $58M supported by OrbiMed
Key Investors in InspireMD
OrbiMed
OrbiMed is a specialized investment firm with a deep focus on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. The firm's investment approach combines financial acumen with extensive industry knowledge to support companies at various stages of development.
What's next for InspireMD?
The recent major strategic investment signifies a strong vote of confidence in InspireMD's technological advancements and market potential. This backing is anticipated to fuel the company's expansion efforts, potentially including scaling manufacturing capabilities, broadening clinical trial initiatives, and enhancing its sales and marketing infrastructure. The company's focus on improving patient outcomes in vascular and coronary interventions positions it to capture significant market share. Future developments will likely center on regulatory approvals, market penetration, and the continued refinement of its MicroNet stent platform to address unmet clinical needs in cardiovascular care.
See full InspireMD company page
